Prognostic factors of sarcomas occurring in bone and joint: A SEER based study
Hongfei Zhou,Shaohui He,Dan Zhang,Jing Wang,Xinghai Yang,Jian Jiao,Wei Xu,Jian Yang,Jianru Xiao
DOI: https://doi.org/10.1097/md.0000000000034231
IF: 1.6
2024-02-10
Medicine
Abstract:Sarcomas are a group of cancers that arise from mesenchymal cells in almost every tissue of the body, and can differentiate along numerous tissue lineages, including fibrous, muscle, bone, and cartilage. Primary sarcomas occurring in the bone include osteosarcoma, chondrosarcoma, Ewing sarcoma, and soft tissue sarcomas (including fibrosarcoma, angiosarcoma, leiomyosarcoma, liposarcoma, etc). [ 1 ] They account for approximately 0.2% of all malignancies diagnosed each year and are associated with significant mortality, with approximately 3000 bone sarcomas newly diagnosed annually in the United States, resulting in 1500 deaths each year. [ 2 , 3 ] Osteosarcoma is the most common primary sarcomas occurring in the bone with a incidence of 0.3 cases per 100,000/year and there is a male predominance. However, the incidence of osteosarcoma in adolescents is higher with 0.8 to 1.1 cases per 100,000/year at age 15 to 19 years. [ 4 ] Chondrosarcoma is the most frequent bone sarcoma of adulthood with a incidence of ∼0.2 cases per 100,000/year, with a median age at diagnosis between 30 and 60 years and no gender predominance. [ 5 ] Ewing sarcoma is the third most common primary sarcomas occurring in the bone with a incidence of ∼0.1 cases per 100,000/year and occurs most frequently in children and adolescents with a male predominance. [ 6 ] Several studies have evaluated prognostic factors in survivors of Ewing sarcoma, [ 7 ] chondrosarcoma, [ 8 , 9 ] rhabdomyosarcoma, [ 10 ] and other soft tissue sarcomas. [ 11 , 12 ] However, given the relative infrequency of bone sarcomas, previous studies have been limited by modest sample sizes, and there have been no population-based comprehensive analyses focusing on all kinds of sarcomas occurring in the bone or joint. The objectives of this study were to characterize the epidemiology of bone sarcomas and to identify prognostic factors, which have potential benefits for patients, healthcare providers, and the field of oncology
medicine, general & internal